Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stroke trials: what have we learned?

Ramesh Madhavan1, Bradley S Jacobs, Steven R Levine

  • 1Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA.

Neurological Research
|June 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DWI Positivity in Mild, Nondisabling Acute Cerebral Ischemia: Data From the PRISMS Trial.

Stroke (Hoboken, N.J.)·2026
Same author

Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos.

Journal of the American College of Cardiology·2025
Same author

Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Current rheumatology reports·2025
Same author

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Arthritis care & research·2025
Same author

Ischaemic brain neuroprotection: a true therapeutic frontier?

Lancet (London, England)·2025
Same author

Ischemic strokes due to pulmonary arteriovenous malformations: A systematic review.

Brain circulation·2024

Intravenous thrombolytic therapy, including tissue plasminogen activator (tPA), shows promise for acute ischemic stroke. Adherence to the NINDS tPA study protocol is crucial for maximizing benefits and minimizing risks in clinical practice.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Ischemic stroke treatment has rapidly evolved with the advent of intravenous thrombolytic therapies.
  • Tissue plasminogen activator (tPA) and ancrod represent key pharmacological interventions evaluated in major clinical trials.

Purpose of the Study:

  • To review major therapeutic trials of intravenous thrombolytic agents for acute ischemic stroke.
  • To assess the clinical practice experience with intravenous tPA post-Food and Drug Administration (FDA) approval.

Main Methods:

  • Systematic review of randomized, controlled trials (RCTs) for acute ischemic stroke treatment.
  • Inclusion of post-FDA approval studies evaluating intravenous tPA in real-world settings.
  • Focus on pivotal trials like the NINDS study for tPA and the STAT trial for ancrod.

Related Experiment Videos

Main Results:

  • The National Institute of Neurological Disorders and Stroke (NINDS) study was the sole trial demonstrating significantly improved patient recovery with intravenous tPA at three months.
  • The STAT trial was a primary study investigating ancrod for ischemic stroke.
  • Community-based studies highlight that benefits of tPA are contingent upon strict adherence to the NINDS protocol.

Conclusions:

  • Intravenous tPA, when administered according to the NINDS protocol, offers significant benefits for acute ischemic stroke patients.
  • Deviations from the established protocol in clinical practice may negate the therapeutic advantages of tPA and increase potential risks.
  • Careful patient selection and protocol adherence are paramount for successful thrombolytic therapy in ischemic stroke.